CANF logo

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares


CANF: Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).


Show CANF Financials

Consumer Interest
SEC Filings

Recent trades of CANF by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by CANF's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of CANF in WallStreetBets Daily Discussion


Recent insights relating to CANF

CNBC Recommendations

Recent picks made for CANF stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CANF

Corporate Flights

Flights by private jets registered to CANF